RT Journal Article
SR Electronic
T1 Investigation of convergent and divergent genetic influences underlying schizophrenia and alcohol use disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.27.20220186
DO 10.1101/2020.10.27.20220186
A1 Emma C. Johnson
A1 Manav Kapoor
A1 Alexander S. Hatoum
A1 Hang Zhou
A1 Renato Polimanti
A1 Frank R. Wendt
A1 Raymond K. Walters
A1 Dongbing Lai
A1 Rachel L. Kember
A1 Sarah Hartz
A1 Jacquelyn L. Meyers
A1 Roseann E. Peterson
A1 Stephan Ripke
A1 Tim B. Bigdeli
A1 Ayman H. Fanous
A1 Carlos N. Pato
A1 Michele T. Pato
A1 Alison M. Goate
A1 Henry R. Kranzler
A1 Michael C. O’Donovan
A1 James T.R. Walters
A1 Joel Gelernter
A1 Howard J. Edenberg
A1 Arpana Agrawal
YR 2020
UL http://medrxiv.org/content/early/2020/12/16/2020.10.27.20220186.abstract
AB Background Alcohol use disorder (AUD) and schizophrenia (SCZ) frequently co-occur, and recent genome-wide association studies (GWAS) have identified significant genetic correlations between them.Methods We used the largest published GWAS for AUD (total cases = 77,822) and SCZ (total cases = 46,827) to systematically identify genetic variants that influence both disorders (in either the same or opposite direction of effect) as well as disorder-specific loci.Results We identified 55 independent genome-wide significant SNPs with the same direction of effect on AUD and SCZ, 8 with robust effects in opposite directions, and 98 with disorder-specific effects. We also found evidence for 12 genes whose pleiotropic associations with AUD and SCZ are consistent with mediation via gene expression in the prefrontal cortex. The genetic covariance between AUD and SCZ was concentrated in genomic regions functional in brain tissues (p = 0.001).Conclusions Our findings provide further evidence that SCZ shares meaningful genetic overlap with AUD, and suggest that genetic variants with an effect on both disorders are expressed in brain tissues.Competing Interest StatementDr. Kranzler is a member of an advisory board for Dicerna Pharmaceuticals and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Dicerna, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. Dr. Kranzler and Dr. Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. Drs. Johnson, Kapoor, Hatoum, Zhou, Polimanti, Wendt, R.K. Walters, Lai, Kember, Hartz, Meyers, Peterson, Ripke, Bigdeli, Fanous, C.N. Pato, M.T. Pato, Goate, O’Donovan, J.T.R. Walters, Edenberg, and Agrawal have no disclosures or conflicts of interest to report.Funding StatementECJ was supported by grant F32AA027435. RP was supported by R21DA047527 and R21DC018098. FRW was supported by F32MH122058. AA is supported by K02DA032573. REP is supported by NIMH K01MH113848 and The Brain & Behavior Research Foundation NARSAD grant 28632 P&S Fund. This work was conducted using the summary statistics from the Psychiatric Genomics Consortium’s Substance Use Disorders Working group. The Psychiatric Genomics Consortium’s Substance Use Disorders (PGC-SUD) working group is supported by MH109532 with funding from NIMH and NIDA. The GPC was supported by grants R01 MH085548 and R01 MH104964 from the National Institute of Mental Health (NIMH), and genotyping of samples was provided by the Stanley Center for Psychiatric Research at Broad Institute. COGS was supported by grants R01 MH065571, R01 MH065588, R01 MH065562, R01 MH065707, R01 MH065554, R01 MH065578, R01 MH065558, R01 MH86135, and R01 MH094320 from the National Institute of Mental Health. Funding support for the Whole Genome Association Study of Bipolar Disorder and the Genome-Wide Association of Schizophrenia Study was provided by the NIMH (R01 MH67257, R01 MH59588, R01 MH59571, R01 MH59565, R01 MH59587, R01 MH60870, R01 MH59566, R01 MH59586, R01 MH61675, R01 MH60879, R01 MH81800, U01 MH46276, U01 MH46289, U01 MH46318, U01 MH79469, and U01 MH79470) and the genotyping of samples was provided through the Genetic Association Information Network (GAIN). This research is based, in part, on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, with support from award #I01 BX003341 and the VISN 4 Mental Illness Research, Education and Clinical Center. This publication does not represent the views of the Department of Veterans Affairs or the United States Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board at Washington University School of Medicine and was done in accordance with all relevant ethical regulations. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the PGC are available for download here: https://www.med.unc.edu/pgc/data-index/ Data from MVP are available for download from dbGAP. Data from the GPC are available by request to the Genomic Psychiatry Cohort. Data from Pardiñas et al. are available for download here: https://walters.psycm.cf.ac.uk